Scholarlink

Background <p>We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. Analysis of public colorectal cancer datasets confirms the existence of a oncofetal signature consisting of 28 upregulated and 8 downregulated genes that stratify patients with worse prognosis.</p> Methods <p>We have generated and analyzed a metacohort which integrates 1118 samples from six colorectal cancer public datasets and performed qPCR analysis of paraffin-embedded and plasma samples from our in-house cohort of colorectal cancer tumors.</p> Results <p>We uncovered a core oncofetal signature, which we have called ColoStem, composed of 5 genes upregulated and 3 genes downregulated that displays prognosis value in a multivariate analysis. We also defined EpiColoStem, a reduction of ColoStem, as a pure epithelial signature with comparable prognosis value as ColoStem. By qPCR analysis of RNA extracted from paraffin-embedded tissues, we demonstrated the actual possibility of using ColoStem and EpiColoStem to refine the prognosis of CRC patients with a simple an affordable method. Initial analysis of plasma samples indicated that both signatures could be adapted for its use in liquid biopsy.</p> Conclusions <p>Our results reveal ColoStem and EpiColoStem tests as valuable tools for refining patient prognosis through the identification of fetal-type CRC tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Laura Solé,
  • Eric Canton,
  • María Maqueda,
  • Teresa Lobo-Jarne,
  • Antonio Barbáchano,
  • Ferran Torres,
  • Julia-Jié Cabré-Romans,
  • Ángela Montoto,
  • Lierni Fernández-Ibarrondo,
  • Daniel Martínez-Garcia,
  • Marta Guix,
  • Mónica Larrubia-Loring,
  • Clara Montagut,
  • Alberto Muñoz,
  • Anna Bigas,
  • Mar Iglesias,
  • Beatriz Bellosillo,
  • Lluís Espinosa

摘要

Background

We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. Analysis of public colorectal cancer datasets confirms the existence of a oncofetal signature consisting of 28 upregulated and 8 downregulated genes that stratify patients with worse prognosis.

Methods

We have generated and analyzed a metacohort which integrates 1118 samples from six colorectal cancer public datasets and performed qPCR analysis of paraffin-embedded and plasma samples from our in-house cohort of colorectal cancer tumors.

Results

We uncovered a core oncofetal signature, which we have called ColoStem, composed of 5 genes upregulated and 3 genes downregulated that displays prognosis value in a multivariate analysis. We also defined EpiColoStem, a reduction of ColoStem, as a pure epithelial signature with comparable prognosis value as ColoStem. By qPCR analysis of RNA extracted from paraffin-embedded tissues, we demonstrated the actual possibility of using ColoStem and EpiColoStem to refine the prognosis of CRC patients with a simple an affordable method. Initial analysis of plasma samples indicated that both signatures could be adapted for its use in liquid biopsy.

Conclusions

Our results reveal ColoStem and EpiColoStem tests as valuable tools for refining patient prognosis through the identification of fetal-type CRC tumors.